Enter Wall Street with StreetInsider Premium. Claim your one week free trial here.
Industry veteran Lauren Silvernail brings over 30 years of experience in financial leadership roles in life sciences and related companies
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell activators, today announced the appointment of Lauren Silvernail to its Board of Directors and as Chair of its Audit Committee.
“We welcome Lauren to our Board of Directors. His strategic, operational and financial experience in the life sciences industry will be a great asset,” said Julie Eastland, President and CEO of Harpoon Therapeutics. “We look forward to Lauren’s guidance as we continue to execute our business plan and advance our new class of T-cell engagers into clinical trials.”
Lauren Silvernail has three decades of experience in financial leadership and business development roles. She has led and played key roles in a wide range of transactions including mergers, acquisitions and financings. She most recently served as Chief Financial Officer and Executive Vice President of Corporate Development for Evolus, Inc., an aesthetic medicine company, where she led fundraising activities and helped establish the infrastructure. for the commercial launch in the United States of the company’s first approved product. Previously, she served as Chief Financial Officer and Chief Commercial Officer at Revance Therapeutics, Inc. and held corporate development positions at ISTA Pharmaceuticals Inc., Allergan and other companies. Lauren is currently a board member of Nicox SA, an international ophthalmology company. She holds an MBA in finance and accounting from the Anderson Graduate School of Management at UCLA and a BA in biophysics from the University of California, Berkeley.
“My experience has shown me that sound science and passionate people are needed for a company to accomplish its mission, and I believe Harpoon’s proprietary platforms and dedicated workforce represent a company on path to success,” said Lauren Silvernail. “I am thrilled to partner with Julie and my fellow board members as we continue to advance Harpoon’s T-cell engager pipeline.”
About Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a new class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are modified proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary trispecific T cell activating construct (TriTAC®), Harpoon is developing a pipeline of new TriTACs initially focused on the treatment of solid tumors and hematological malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T-cell engager that remains dormant until it reaches the tumor. Harpoon’s third proprietary technology platform, Sustained-Release TriTAC-XR, is designed to alleviate cytokine release syndrome. For more information about Harpoon Therapeutics, please visit www.harpoontx.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe”, “expect”, “plan”, “target”, “will” and similar expressions (as well as that other words or phrases that refer to future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Harpoon Therapeutics’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Harpoon Therapeutics’ future clinical development programs, results or performance to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements regarding the development and advancement of Harpoon Therapeutics’ platforms and product candidates, Harpoon Therapeutics’ business prospects, and expectations regarding further Harpoon’s management team and other statements that are not historical facts. Many factors could cause current expectations to differ from actual results, including unexpected safety or efficacy data observed during clinical studies, preliminary data and trends may not be predictive of the data or future results, may not demonstrate safety or efficacy or lead to regulatory approval by the FDA or other regulatory agencies, clinical trial site activation or enrollment rates below expectations, unforeseen or greater than the impacts or delays due to COVID-19, changes in anticipated or existing competition, changes in the regulatory environment, uncertainties and timing of the regulatory approval process, timing and results of unexpected or other litigation conflicts, and the adequacy of cash resources of Harpoon Therapeutics. These and other factors that may cause Harpoon Therapeutics’ actual results to differ from those expressed or implied by the forward-looking statements in this press release are discussed in Harpoon Therapeutics’ filings with the Securities and Exchange. United States Commission, including under “Risk Factors”. in Harpoon Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 and Harpoon Therapeutics’ future filings. Except as required by law, Harpoon Therapeutics undertakes no obligation to update the forward-looking statements contained herein to reflect any change in expectations, even when new information becomes available.
Robert H. Uhl